Gan & Lee(SH:603087) 智通财经网·2025-08-07 11:08Core Viewpoint - Ganli Pharmaceutical (603087.SH) reported significant growth in its 2025 semi-annual results, with revenue reaching 2.067 billion yuan, a year-on-year increase of 57.18%, and net profit attributable to shareholders at 604 million yuan, up 101.96% [1] Group 1: Financial Performance - Revenue for the reporting period was 2.067 billion yuan, reflecting a 57.18% year-on-year growth [1] - Net profit attributable to shareholders was 604 million yuan, representing a 101.96% increase [1] - Deducted non-recurring net profit reached 488 million yuan, showing a substantial growth of 284.47% [1] - Basic earnings per share stood at 1.02 yuan [1] Group 2: Domestic Sales - Domestic sales revenue amounted to 1.845 billion yuan, an increase of 655 million yuan, or 55.28% year-on-year [1] - Domestic formulation sales revenue was 1.802 billion yuan, up 57.09% compared to the previous year [1] - The company successfully expanded its market share through two rounds of insulin centralized procurement, with the first-year procurement agreement volume increasing by 32.6% in the 2024 follow-up procurement [1] - The impact of sales volume growth on revenue was 385 million yuan, while price growth contributed 270 million yuan [1] - Overall domestic formulation sales volume increased by 33.55%, with all formulation products showing positive growth [1] Group 3: International Sales - International revenue reached 222 million yuan, an increase of 95 million yuan, or 75.08% year-on-year [2] - The growth in international revenue was driven by the company's ongoing global strategy [2] - The company deepened stable partnerships with key market leaders, leveraging customer trust to promote a diverse product portfolio and explore new growth opportunities [2]